The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction
Metrics: PDF 1529 views | HTML 2277 views | ?
Jean-Baptiste Oudart1,2, Manon Doué1, Alexia Vautrin1, Bertrand Brassart1, Christèle Sellier1, Aurelie Dupont-Deshorgue1, Jean-Claude Monboisse1,2, François-Xavier Maquart1,2, Sylvie Brassart-Pasco1, Laurent Ramont1,2
1Université de Reims Champagne-Ardenne, CNRS UMR 7369 (Matrice Extracellulaire et Dynamique Cellulaire, MEDyC), Reims, France
2CHU de Reims, Laboratoire Central de Biochimie, Reims, France
Laurent Ramont, e-mail: email@example.com
Keywords: collagen XIX, NC1 domain, integrin, FAK/PI3K/Akt/mTOR, tumor invasion
Received: April 24, 2015 Accepted: November 14, 2015 Published: November 26, 2015
Type XIX collagen is a minor collagen associated with basement membranes. It was isolated for the first time in a human cDNA library from rhabdomyosarcoma and belongs to the FACITs family (Fibril Associated Collagens with Interrupted Triple Helices). Previously, we demonstrated that the NC1 domain of collagen XIX (NC1(XIX)) exerts anti-tumor properties on melanoma cells by inhibiting their migration and invasion. In the present work, we identified for the first time the integrin αvβ3 as a receptor of NC1(XIX). Moreover, we demonstrated that NC1(XIX) inhibits the FAK/PI3K/Akt/mTOR pathway, by decreasing the phosphorylation and activity of the major proteins involved in this pathway. On the other hand, NC1(XIX) induced an increase of GSK3β activity by decreasing its degree of phosphorylation. Treatments targeting this central signaling pathway in the development of melanoma are promising and new molecules should be developed. NC1(XIX) seems to have the potential for the design of new anti-cancer drugs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.